SecBot SecBot

MDCX

Medicus Pharma Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. A6· CIK 0001997296 Biotech & Drug Discovery
$2.51 +0.01 (+0.40%)
Oct 26 4:00 PM ET · prev $2.50
Market cap
$5.0M
Nano cap
Median target
$175.00
+6872% · range $15.00–450.00
Next earnings
Nov 9
in 13 days · EPS est. −$6.50
1 year
−97.9%
from $119.50 · Oct 27
30 days
−67.0%
from $7.60
52-week range
$2.50–123.50
−98% from high · low Oct 23
Avg volume 20D
88.2K
Oct 9 spike 346.6K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 8 reports · 90 days
Balance 1 bearish · 2 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 6/8 ·Next Earnings date, Nov 9, 2026
Strongest NEUTRAL Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, after failing to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    69% below its 50-day average. New closing low $2.50 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCADD25,102$11.2K
MORGAN STANLEYNEAR_EXIT1,022$456.00
WELLS FARGO & COMPANY/MNDOUBLED200$89.00
Private Advisor Group, LLCADD240,055$110.2K
COMMONWEALTH EQUITY SERVICES, LLCADD48,143$22.1K
UBS Group AGDOUBLED40,441$18.6K
MORGAN STANLEYTRIM5,468$2.5K
BlackRock, Inc.DOUBLED34,317$52.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Apr 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +6872%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Apr 20, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 19, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Mar 9, 2026D. Boral Capital
MAINTAIN
MAINTAINBuy
Dec 15, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Nov 17, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy
Nov 13, 2025D. Boral Capital
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Sep 4, 2026
Smith Andrew Alasdair
Chief Operating Officer
AWARD$125.4K
Sep 4, 2026
Smith Andrew Alasdair
Chief Operating Officer
AWARD125,000 sh
Sep 4, 2026
Bokhari Raza
Chief Executive Officer
AWARD$501.5K
Sep 4, 2026
Bokhari Raza
Chief Executive Officer
AWARD500,000 sh
Sep 4, 2026
Bonner Carolyn F.
President and CFO
AWARD$250.7K
Sep 4, 2026
Bonner Carolyn F.
President and CFO
AWARD250,000 sh
Sep 4, 2026
Brennan Edward J.
Chief Scientific Officer
AWARD$100.3K
Sep 4, 2026
Brennan Edward J.
Chief Scientific Officer
AWARD100,000 sh

Earnings setup

Estimates
Nov 9
reports in 13 days
−$6.50
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$6.50-$6.50–-$6.50+23.5%$0.00
Next Q-$5.11-$7.50–-$0.82+1.2%$0.00
Current FY-$27.00-$27.00–-$27.00+14.3%$0.00
Next FY-$13.61-$25.00–-$0.83+7.2%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 9, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Other
🔒 Fresh data, subscribers only
Oct 23, 2026 SEC
Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, after failing to meet the…
8-K — Impact 5/10
Oct 16, 2026 SEC
Medicus Pharma Ltd. filed an 8-K reporting a 1-for-50 reverse stock split (share consolidation) effective October 12…
8-K — Impact 3/10
Oct 16, 2026 SEC
Kenneth R. Melani and Velocity Fund Partners, LP filed a Schedule 13G/A disclosing a combined 3.6% stake (3,248,741…
SC 13G/A — Impact 3/10
Sep 10, 2026 Press
Medicus Pharma published the abridged Clinical Study Report for its Phase 2 SkinJect® trial on ClinicalTrials.gov…
Impact 6/10
Sep 4, 2026 Insider
Smith Andrew Alasdair was granted 735,294 shares
Chief Operating Officer @ $0.1705 ($125.4K)
Sep 4, 2026 Insider
Smith Andrew Alasdair was granted 125,000 shares
Chief Operating Officer
Sep 4, 2026 Insider
Bokhari Raza was granted 2,941,176 shares
Chief Executive Officer @ $0.1705 ($501.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
MDCX Q3 2026 Earnings Scheduled — 2026-11-09
Recent
Oct 26, 2026
Press release
🔒 Fresh data, subscribers only
Oct 12, 2026
Trading halt
Halt Resumed: MDCX — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-09T23:50:00.000Z | Resumed 2026-10-12T13:00:00.000Z
Oct 9, 2026
Trading halt
Trading Halt: MDCX — T3 (News and Resumption Times)
Medicus Pharma Ltd Common Stk | Market: NASDAQ | Code: T3 — News and Resumption Times
Sep 30, 2026
Short interest
Short Interest: MDCX down 26% to 3.7M shares
Settlement 2026-09-30 | Days to cover: 1.00 | ≈5.14% of shares outstanding (est.)
Sep 21, 2026
Press release
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
Decision advances Company’s previously announced capital-efficient development strategy by concentrating resources on FDA-authorized, SKNJCT-005…

SecBot reports

7 filings · 9 press releases · 1 bullish · 1 bearish · 5 neutral
All MDCX filing & press-release reports (16)